All In Biotech

Drug Trial Radar · NCT07080242

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 28, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
SystImmune Inc.Industry
Sponsor type
Industry
First posted
Jul 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Conditions

  • Small Cell Lung Cancer Metastatic or Locally Advanced
  • Neuroendocrine Cancer
  • Metastatic Neuroendocrine Prostate Cancer
  • Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
  • Metastatic Advanced Merkel Cell Carcinoma
  • Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung
  • Locally Advanced Extrapulmonary Neuroendocrine Carcinoma
  • Locally Advanced Neuroendocrine Prostate Cancer
  • Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine
  • Locally Advanced Merkel Cell Carcinoma
  • Metastatic Large Cell Neuroendocrine Carcinoma of the Lung

Interventions

  • BL-M14D1Drug

    BL-M14D1 will be administered on D1 every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess safety and tolerability of BL-M14D1Time frame: 18 months

Locations

32 sites in 3 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • OPN Healthcare

    Glendale, California · Recruiting

  • MemorialCare Long Beach Medical Center

    Long Beach, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • UCLA

    Los Angeles, California · Recruiting

  • UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center)

    San Francisco, California · Recruiting

  • University of Colorado - Anschutz Cancer Pavilion

    Aurora, Colorado · Recruiting

  • Valkyrie Denver

    Lakewood, Colorado · Not yet recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Emory Winship

    Atlanta, Georgia · Recruiting

  • Tulane School of Medicine

    New Orleans, Louisiana · Recruiting

  • START - New Jersey

    East Brunswick, New Jersey · Recruiting

  • John Theurer Cancer Center-Hackensack

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Providence Cancer Institute

    Portland, Oregon · Recruiting

  • Prisma Health Cancer Institute

    Greenville, South Carolina · Recruiting

  • NEXT Dallas

    Dallas, Texas · Recruiting

  • START Dallas- Fort Worth

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Houston

    Houston, Texas · Recruiting

  • START- San Antonio

    San Antonio, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • University of Washington/Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • LTD "High Technology Hospital Medcenter"

    Batumi, Georgia · Recruiting

  • JSC "Vian"

    Kutaisi, Georgia · Recruiting

  • LTD "New Hospitals"

    Tbilisi, Georgia · Recruiting

  • LTD "Pineo Medical Ecosystem"

    Tbilisi, Georgia · Recruiting

  • LLC "Caucasus Medical Centre"

    Tbilisi, Georgia · Recruiting

  • Regional Municipal Nonprofit Enterprise "Bukovinian clinical oncology center" of the Chernivtsi Regional Council

    Chernivtsi, Ukraine · Not yet recruiting

  • "The Municipal Enterprise "Volyn Regional Clinical Hospital" of the Volyn Regional Council, Regional Medical Oncology Centre"

    Lutsk, Ukraine · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.